Cited by 128Parkinson's Disease Mechanisms and TreatmentsGut microbiota and healthGastrointestinal motility and disorders

Fecal Microbiota Transplantation for Treatment of Parkinson Disease: A Randomized Clinical Trial

Open access
Scheperjans, Filip, Levo, Reeta, Bosch, Berta, Lääperi, Mitja, Pereira, Pedro A. B., Smolander, Olli-Pekka, Aho, Velma T. E., Vetkas, Nora +8 more·2024·JAMA Neurology

Abstract

Importance: Dysbiosis has been robustly demonstrated in Parkinson disease (PD), and fecal microbiota transplantation (FMT) has shown promising effects in preclinical PD models. Objective: To assess the safety and symptomatic efficacy of colonic single-dose anaerobically prepared FMT. Design, Setting, and Participants: This was a double-blind, placebo-controlled, randomized clinical trial conducted between November 2020 and June 2023 with a follow-up period of 12 months at 4 hospitals in Finland. Patients with PD aged 35 to 75 years in Hoehn & Yahr stage 1-3 with a mild to moderate symptom burden and dysbiosis of fecal microbiota were included. Of 229 patients screened, 48 were randomized and 47 received the intervention. One patient discontinued due to worsening of PD symptoms. Two further patients were excluded before analysis and 45 were included in the intention-to-treat analysis. Intervention: Participants were randomized in a 2:1 ratio to receive FMT or placebo via colonoscopy. Main Outcomes and Measures: The primary end point was the change of Movement Disorder Society Unified Parkinson’s Disease Rating Scale parts I-III (part III off medication) at 6 months. Safety was assessed by recording adverse events (AEs). Results: The median (IQR) age was 65 (52.5-70.0) years in the placebo group and 66 (59.25-69.75) years in the FMT group; 9 (60.0%) and 16 (53.3%) patients were male in the placebo group and the FMT group, respectively. The primary outcome did not differ between the groups (0.97 points, 95% CI, −5.10 to 7.03, P = .75). Gastrointestinal AEs were more frequent in the FMT group (16 [53%] vs 1 [7%]; P = .003). Secondary outcomes and post hoc analyses showed stronger increase of dopaminergic medication and improvement of certain motor and nonmotor outcomes in the placebo group. Microbiota changes were more pronounced after FMT but differed by donor. Nevertheless, dysbiosis status was reversed more frequently in the placebo group. Conclusions and Relevance: FMT was safe but did not offer clinically meaningful improvements. Further studies—for example, through modified FMT approaches or bowel cleansing—are warranted regarding the specific impact of donor microbiota composition and dysbiosis conversion on motor and nonmotor outcomes as well as medication needs in PD. Trial Registration: ClinicalTrials.gov Identifier: NCT04854291

Integrity signals

Registry

Crossref · 10.1001/jamaneurol.2024.2305

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • There are currently four RCTs with available evidence for the role of FMT in treating PD.

    “There are currently four RCTs with available evidence for the role of FMT in treating PD [206–209].”
  • Three of these RCTs reported changes in global or motor function, and of these two reported significant improvement UPDRS PD symptom scores at 12 weeks and 12 months, respectively.

    “Three of these reported changes in global or motor function, and of these two reported significant improvement UPDRS PD symptom scores at 12 weeks and 12 months, respectively.”
  • One study reported no changes in motor function at 6 months post-FMT, although here the treatment group required smaller dose increases than placebo.

    “One study reported no changes in motor function at 6 months post-FMT, although here the treatment group required smaller dose increases than placebo.”
  • In these studies, the clinical findings were associated with a shift toward anti-inflammatory microbial species.

    “In these studies, the clinical findings were associated with a shift toward anti-inflammatory microbial species.”
  • The FMT treatment failed to produce a significant change in the gut microbiome in that study.

    “In this study, only 3% of the treatment group were reported to show a change from dysbiotic to non-dysbiotic status, compared to 33% in the placebo arm, suggesting that the FMT treatment failed to produce a significant change in the gut microbiome.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Scheperjans, F., Levo, R., Bosch, B., Lääperi, M., Pereira, P. A. B., Smolander, O.-P., Aho, V. T. E., Vetkas, N., Toivio, L., Kainulainen, V., Fedorova, T. D., Lahtinen, P., Ortiz, R., Kaasinen, V., Satokari, R., & Arkkila, P.
Affiliations
  • University of Helsinki (FI)
  • Helsinki University Hospital (FI)
  • Lääperi Statistical Consulting, Helsinki, Finland
  • Aarhus University (DK)
  • Päijät-Hämeen Keskussairaala (FI)
  • Tampere University Hospital (FI)
  • University of Turku (FI)
Corresponding author
Scheperjans, Filip
Venue
JAMA Neurology
Published
2024-09-01
Volume
81
Issue
9
Pages
925
ISSN
2168-6149 (ISSN-L)
OpenAlex
W4401075949
Cited by
128
References
47
Citations by year
2026: 58 · 2025: 60 · 2024: 10
FWCI
34.25
Type
journal article
Language
en
Open access
Locations
  • JAMA Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion)
  • Tampere University Institutional Repository (Tampere University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
fecal microbiota transplantation, Parkinson's disease, gut dysbiosis, microbiota, MDS-UPDRS, motor symptoms, non-motor symptoms, dopaminergic therapy, gastrointestinal adverse effects, donor microbiota, treatment safety, treatment efficacy, bowel preparation
MeSH terms
Fecal Microbiota Transplantation, Adult, Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Parkinson Disease, Treatment Outcome, Dysbiosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review